Clinical Trial Update: Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract [Phase 1]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1B study of B-701 in combination with pembrolizumab for metastatic bladder/urothelial tract cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma

Drugs mentioned

• B-701
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Mark Pomerantz, MD | Conditions: Bladder Cancer | Phase 1 | Status: TERMINATED